Davies Emma, Phillips Ceri, Rance Jaynie, Sewell Berni
College of Human and Health Sciences, Swansea University, Swansea, UK.
Swansea Centre for Health Economics, College of Human and Health Sciences, Swansea University, Swansea, UK.
Br J Pain. 2019 Aug;13(3):145-158. doi: 10.1177/2049463718800737. Epub 2018 Sep 25.
To examine trends in strong opioid prescribing in a primary care population in Wales and identify if factors such as age, deprivation and recorded diagnosis of depression or anxiety may have influenced any changes noted.
Trend, cross-sectional and longitudinal analyses of routine data from the Primary Care General Practice database and accessed via the Secure Anonymised Information Linkage (SAIL) databank.
A total of 345 Primary Care practices in Wales.
Anonymised records of 1,223,503 people aged 18 or over, receiving at least one opioid prescription between 1 January 2005 and 31 December 2015 were analysed. People with a cancer diagnosis (10.1%) were excluded from the detailed analysis.
During the study period, 26,180,200 opioid prescriptions were issued to 1,223,503 individuals (55.9% female, 89.9% non-cancer diagnoses). The greatest increase in annual prescribing was in the 18-24 age group (10,470%), from 0.08 to 8.3 prescriptions/1000 population, although the 85+ age group had the highest prescribing rates across the study period (from 149.9 to 288.5 prescriptions/1000 population). The number of people with recorded diagnoses of depression or anxiety and prescribed strong opioids increased from 1.2 to 5.1 people/1000 population (328%). The increase was 366.9% in areas of highest deprivation compared to 310.3 in the least. Areas of greatest deprivation had more than twice the rate of strong opioid prescribing than the least deprived areas of Wales.
The study highlights a large increase in strong opioid prescribing for non-cancer pain, in Wales between 2005 and 2015. Population groups of interest include the youngest and oldest adult age groups and people with depression or anxiety particularly if living in the most deprived communities. Based on this evidence, development of a Welsh national guidance on safe and rational prescribing of opioids in chronic pain would be advisable to prevent further escalation of these medicines.
This is the first large-scale, observational study of opioid prescribing in Wales.Over 1 million individual, anonymised medical records have been searched in order to develop the study cohort, thus reducing recall bias.Diagnosis and intervention coding in the Primary Care General Practice database is limited at input and may lead to under-reporting of diagnoses.There are limitations to the data available through the Secure Anonymised Information Linkage databank because anonymously linked dispensing data (what people collect from the pharmacy) are not currently available. Consequently, the results presented here could be seen as an 'intention to treat' and may under- or overestimate what people in Wales actually consume.
研究威尔士初级保健人群中强效阿片类药物处方的趋势,并确定年龄、贫困程度以及记录在案的抑郁症或焦虑症诊断等因素是否可能影响所观察到的任何变化。
对初级保健全科医疗数据库的常规数据进行趋势分析、横断面分析和纵向分析,数据通过安全匿名信息链接(SAIL)数据库获取。
威尔士的345家初级保健机构。
对2005年1月1日至2015年12月31日期间至少接受过一次阿片类药物处方的1,223,503名18岁及以上人群的匿名记录进行分析。患有癌症诊断的人群(10.1%)被排除在详细分析之外。
在研究期间,共向1,223,503人开具了26,180,200份阿片类药物处方(女性占55.9%,非癌症诊断者占89.9%)。年处方量增长最大的是18 - 24岁年龄组(增长10,470%),从每1000人0.08张处方增至8.3张,不过在整个研究期间,85岁及以上年龄组的处方率最高(从每1000人149.9张增至288.5张)。记录有抑郁症或焦虑症诊断且开具强效阿片类药物的人数从每千人口1.2人增至5.1人(增长328%)。贫困程度最高地区的增长为366.9%,而最贫困地区为310.3%。威尔士贫困程度最高地区的强效阿片类药物处方率是最不贫困地区的两倍多。
该研究突出显示,2005年至2015年期间威尔士非癌症疼痛的强效阿片类药物处方量大幅增加。值得关注的人群包括最年轻和最年长的成年年龄组以及患有抑郁症或焦虑症的人群,尤其是生活在最贫困社区的此类人群。基于这些证据,制定威尔士关于慢性疼痛中阿片类药物安全合理处方的国家指南将是明智之举,以防止这些药物的进一步滥用。
这是威尔士首次对阿片类药物处方进行的大规模观察性研究。为建立研究队列,已检索了超过100万份个人匿名医疗记录,从而减少了回忆偏倚。初级保健全科医疗数据库中的诊断和干预编码在录入时有限,可能导致诊断报告不足。通过安全匿名信息链接数据库获取的数据存在局限性,因为目前无法获得匿名链接的配药数据(人们从药房领取的药物)。因此,此处呈现的结果可被视为“意向性治疗”结果,可能低估或高估威尔士人群的实际用药量。